Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 27:14:158.
doi: 10.3389/fnins.2020.00158. eCollection 2020.

The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis

Gerald A Maguire  1 , Diem L Nguyen  1 , Kevin C Simonson  1 , Troy L Kurz  1
Affiliations
Review

The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis

Gerald A Maguire et al. Front Neurosci. .

Abstract

Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette's Syndrome in that both begin in childhood, follow a similar male to female ratio of 4:1, respond to dopamine antagonists, and symptomatically worsen with dopamine agonists. In recent years, advances in the neurophysiology of stuttering have helped further guide pharmacological treatment. A newer medication with a novel mechanism of action, selective D1 antagonism, is currently being investigated in FDA trials for the treatment of stuttering. D1 antagonists possess different side-effect profiles than D2 antagonist medications and may provide a unique option for those who stutter. In addition, VMAT-2 inhibitors alter dopamine transmission in a unique mechanism of action that offers a promising treatment avenue in stuttering. This review seeks to highlight the different treatment options to help guide the practicing clinician in the treatment of stuttering.

Keywords: aripiprazole; ecopipam; medication; olanzapine; pharmacologic; risperidone; stuttering.

PubMed Disclaimer

References

    1. Alm P. A. (2004). Stuttering and the basal ganglia circuits: a critical review of possible relations. J. Commun. Disord. 37 325–369. 10.1016/j.jcomdis.2004.03.001 - DOI - PubMed
    1. Althaus M., Vink H. J., Minderaa R. B., Brouwer S. M., Oosterhoff M. D. (1995). Lack of effect of clonidine on stuttering in children. Am. J. Psychiatry 152 1087–1089. 10.1176/ajp.152.7.1087 - DOI - PubMed
    1. American Psychiatric Association Dsm-5 Task Force (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5TM, 5th Edn Washington, DC: American Psychiatric Publishing, Inc.
    1. Andrews G., Craig A. (1988). Prediction of outcome after treatment for stuttering. Br. J. Psychiatry 153 236–240. 10.1192/bjp.153.2.236 - DOI - PubMed
    1. Andrews G., Craig A., Feyer A. M., Hoddinott S., Howie P., Neilson M. (1983). Stuttering: a review of research findings and theories circa 1982. J. Speech Hear Disord. 48 226–246. 10.1044/jshd.4803.226 - DOI - PubMed